The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer

2018 ◽  
Vol 118 (8) ◽  
pp. 1311-1317 ◽  
Author(s):  
Hanumant Chouhan ◽  
Tarik Sammour ◽  
Michelle L Thomas ◽  
James W Moore
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Braf Mutation ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Stage Iii Colon Cancer

Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3598-3598
Author(s):  
Jun Seok Park ◽  
Soo Yeun Park ◽  
Gyu-Seog Choi ◽  
Hye Jin Kim ◽  
Jong Gwang Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Surgical Complication ◽  
Phase Iii ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Stage Iii Colon Cancer

3598 Background: Adjuvant chemotherapy (AC) is recommended to commence within 8 weeks since after surgical resection of stage II or III colon cancer. Results of many retrospective studies showed inferior survival outcomes following delay of AC delay. Moreover, preclinical studies showed that the progression of disseminated cancer cells is profound during the postoperative period. This study is the first prospective trial to evaluate early (≤ 14 days postoperative) AC for patients (pts) with stage III colon cancer. Methods: This study is a prospective, multicenter, randomized phase III trial. Pts with pathological stage III colon cancer were enrolled and randomized 1:1 to early AC (starting AC ≤ 14 days after surgery) or conventional AC (starting AC > 14 days after surgery). Pts were recommended to receive 12 cycles of FOLFOX-6 for AC. The primary endpoint was disease-free survival. The secondary endpoints were overall survival, adverse events, surgical complication during AC, and patient-reported outcomes (quality of life) during 1 year after surgery. Herein, safety data, chemotherapy delivery, and quality of life are presented. Results: This study randomized 443 pts either early AC arm (221pts) or early AC arm (222 pts) to the during September 2011 to March 2020. 380 pts who received at least one cycle of FOLFOX-6 were included in the safety analysis (192 and 188 in the early and conventional AC arms, respectively). The baseline characteristics of the two groups were well-balanced except for the interval from the surgery to the initial AC. The early and conventional AC arms started their first chemotherapy at median of 13 (4-43 days) and 29 (17-53 days) after surgery (p < 0.001), respectively. No significant differences were seen in the median chemotherapy cycles, AC completion, and relative oxaliplatin dose intensity between groups. AC Completion without any change of dose or schedule delay was seen in 18% and 20% in early and conventional AC arms respectively, while dose reduction or delay was 65% and 61%, respectively. Toxicities of grade 3 or more were seen in 28% in both groups. One patient in the early AC arm underwent an emergent operation for anastomotic leakage on the second day of 5-fluorouracil infusion (postoperative day 14). However, the surgical complication was not seen in any other patient. The scores of the European Organization for Research and Treatment of Cancer Quality of Life core 30 questionnaire were similar in both arms at baseline (before starting AC), and 1 month, 3 months, 6 months, and 12 months after surgery. Conclusions: Early AC was safe and did not increase either chemotherapy-related adverse events or surgery-related complications during treatment. Moreover early AC did not reduce the quality of life of the pts during 1 year after surgery. This study continues to follow-up the patients for survival outcomes. Clinical trial information: NCT01460589.

Microsatellite instability status does not predict total lymph node or negative lymph node retrieval in stage III colon cancer

2012 ◽  
Vol 43 (8) ◽  
pp. 1258-1264 ◽  
Author(s):  
Erin MacQuarrie ◽  
Thomas Arnason ◽  
Jennette Gruchy ◽  
Sen Yan ◽  
Arik Drucker ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Microsatellite Instability ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Negative Lymph Node ◽  
Lymph Node Retrieval ◽  
Total Lymph Node

Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes

2016 ◽  
Vol 15 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Joanna Vergidis ◽  
Gillian Gresham ◽  
Howard J. Lim ◽  
Daniel J. Renouf ◽  
Hagen F. Kennecke ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Weight Changes ◽  
Stage Iii Colon Cancer

Microsatellite instability and retrieval of lymph nodes in stage III colon cancer: harbinger or hermit?—reply

2012 ◽  
Vol 43 (10) ◽  
pp. 1786
Author(s):  
Erin MacQuarrie ◽  
Thomas Arnason ◽  
Jennette Gruchy ◽  
Sen Yan ◽  
Arik Drucker ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Nodes ◽  
Microsatellite Instability ◽  
Stage Iii ◽  
Stage Iii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document